HIV Articles  
Back 
 
 
GlaxoSmithKline Introduces HIV Education Initiative for Community-Based AIDS Service Organizations
 
 
  "A Positive Life" Offers Front-Line HIV Community Resources that Draw on Real-World Experiences
 
Contact: Marc Meachem
(919) 483-2839
 
March 20, 2007 - As part of its ongoing commitment to furthering education about HIV, GlaxoSmithKline (GSK) is launching, "A Positive Life," an educational initiative to be delivered through AIDS Service Organizations (ASOs) throughout the United States. For many patients living with HIV and their caregivers, ASOs are the center of their support system and an important resource for the local community.
 
"Having worked in HIV for over 20 years, we at GSK recognize who the real leaders are in the community," said Peter Hare, Vice President, HIV Business Unit, GlaxoSmithKline. "That's why we're renewing our efforts to provide support for ASOs, which are critical to the care and well-being of HIV patients and caregivers in many communities."
 
"A Positive Life" features several elements, including an updated series of patient education materials that will be provided to ASOs, and a new online resource called APositiveLife.com, which provides information about prevention, testing, and living with HIV. In addition, the personal stories of individuals living with and affected by HIV are available as streaming videos on the website; these personal stories provide a first-hand account of how real patients deal with their diagnosis, live with side effects and rely on friends and family for support. These stories along with the disease information on the site will be a resource for HIV positive persons and those who care for them.
 
GSK scientists and physicians are also meeting with ASOs across the country to disseminate disease information about HIV, share updates on treatment options and understand issues facing treatment educators and clients at the local level.
 
"The face-to-face part of this program delivers a complete educational package for ASOs and allows GSK to lend our expertise in HIV to help address local issues and concerns," said Denise Sutherland-Phillips, MD, Manager and Medical Monitor, Clinical Development, HIV Infectious Disease Medicine Development Center at GSK.
 
"A Positive Life" represents the continuation of GSK's efforts to deliver HIV information and resources to communities via AIDS Services Organizations.
 
About GlaxoSmithKline's Work in HIV
GSK has developed more medicines to treat HIV than any other company. A total of eight GSK medicines are available today, many of which are medical "firsts":
- First antiretroviral for HIV treatment
- First medication to be used to help prevent mother to child transmission
- First fixed dose combination treatment for HIV
- First fixed-dose tablet regimen combining three HIV medications.
 
GSK's latest products include a once-a-day fixed dose combination medicine and a protease inhibitor (PI).
 
GSK scientists are constantly looking for new approaches and novel products to combat HIV. The company is developing new medicines in four classes: next generation protease inhibitors , non-nucleoside reverse transcriptase inhibitors, entry inhibitors (CCR5 and CXCR4) and, integrase inhibitors. GSK also has an active HIV vaccine development program.
 
Public-private partnerships have surfaced as the best hope for delivering medical care as well as medicines to the developing world, where HIV and other diseases pose overwhelming health threats. GSK is the only pharmaceutical company conducting research into the top three diseases of the developing world as identified by the World Health Organization (TB, malaria and HIV).
 
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information visit www.gsk.com.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org